Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramipril High Dose vs Ramipril + Telmisartan in Diabetic Hypertension
NCT00208221Phase 3
Key facts
- Status
- Terminated
- Start
- Aug 2006
- Countries
- 1
- Sponsor
- Montreal Clinical Research Institute
- Modality
- Small Molecules
- Drugs
- telmisartan
- Conditions
- hypertension (HTN)albuminuria
01
Overview
Phase 3, randomised, open-label trial of telmisartan in hypertension (HTN) and albuminuria (2 arms), sponsored by Montreal Clinical Research Institute. Primary endpoint: Microalbuminuria. Started Aug 2006; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
Ramipril 20 mg
Ramipril 20 mg daily
Ramipril 10 mg + Telmisartan 80 mg
Ramipril 10 mg + Telmisartan 80 mg daily
03
Who it enrols
Patients with Type 2 Diabetes, Hypertension, and Microalbuminuria. Excludes patients with severe renal or hepatic dysfunction, recent stroke or PTCA, or CHF NYHA III-IV.
04
Endpoints
Primary
Microalbuminuria
Secondary
Plasma renin
Plasma angiotensin
Plasma aldosterone
Plasma catecholamines
Oxidative stress
Diastolic Blood Pressure
Systolic Blood Pressure
Beyond the preview
Go deeper on NCT00208221.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00208221.